RSV Vaccines Provider Fact Sheet & FAQs

Quick Facts

- Two new RSV vaccines, from GSK (Arexvy) Pfizer (Abrysvo) and were FDA approved in May 2023 for adults ≥60
- Both vaccines were generally safe and well-tolerated in phase 3 clinical trials, and demonstrated >80% efficacy against symptomatic, lab-confirmed RSV with documented lower respiratory symptoms
- Both are protein-based (not live) vaccines
- Immunocompromised patients were not included in the trials; efficacy in this group is unknown, and further studies are needed to assess for any specific safety concerns
- The CDC ACIP recommendation regarding the new RSV vaccines is as follows: Adults ≥ 60 and who are at higher risk for severe RSV disease may receive a single dose of RSV vaccine, using shared clinical decision making.

Which patients should be offered the RSV vaccine?

Consistent with CDC ACIP recommendations, we suggest offering the RSV vaccine to adult patients ≥ 60 years old who are at highest risk of severe RSV infection (see below). The RSV vaccine studies (Pfizer and GSK) excluded immunosuppressed individuals, so efficacy and safety are not yet known in this population. Just as with other aspects of their patients’ medical care, providers should discuss the risks and benefits of vaccination with their patients in order to reach a shared decision.

Who is highest risk for severe RSV infection and may benefit the most from vaccination?

Adults at highest risk https://www.cdc.gov/rsv/clinical/index.html for severe RSV infection are those who are 60 years and older with any of the following conditions:

- Moderate or severe immunocompromise
- Chronic hematologic disorders
- Chronic heart, lung, liver, or kidney disease
- Diabetes mellitus, Neurologic or neuromuscular conditions, Adults living in nursing homes or long-term care facilities

What is different about the two available vaccines?

Abrysvo (Pfizer) is a bivalent vaccine containing stabilized prefusion F glycoproteins from the two major co-circulating antigenic subgroups (RSV A and RSV B). Arexvy (GSK) is a monovalent vaccine containing a stabilized prefusion F glycoprotein from the RSV A subgroup, combined with an adjuvant (AS01e) to boost immune responses. The adjuvant used in Arexvy is the same one used in the currently available herpes zoster vaccine (Shingrix).

Is there an advantage of one vaccine over another?

To date there has been no head-to-head comparison of the two available vaccines. It is also unclear which of the vaccines will provide the best protection for immunosuppressed patients. Currently, we cannot recommend one vaccine over another. Eligible patients should be encouraged to get whichever vaccine is available based on formulary or coverage constraints.

What are side effects of the vaccines?
Common side effects of the vaccines in the phase 3 studies, included arm soreness/pain, fatigue, headache, and body aches; fever was uncommon after vaccination. In the vaccine trials, there were 6 severe adverse inflammatory neurologic events (Guillain-Barré syndrome, acute disseminated encephalomyelitis) among 38,247 participants (0.016%). There is also an early signal, suggesting a possible increase in atrial fibrillation (an abnormal heart rhythm). It is unknown whether these rare events were vaccine-related and which patient populations might be most affected.

When I engage in shared decision making with my patient, what are the key factors to consider? How should I discuss this with my patients?
In addition to immunocompromise, the primary risk factors for severe RSV are being elderly and having cardiac or pulmonary comorbidities. Patients who are older and have more than one comorbidity will be at higher risk for adverse outcomes from RSV and may be most likely to benefit from vaccination. Patients who interact frequently with young children may be at higher risk for acquiring RSV. So far, risk factors predisposing individuals to potential RSV vaccine adverse events remain unknown.
These are all considerations when discussing the risks and benefits of vaccination with patients.

Can the RSV vaccine be given at the same time as other vaccines, such as the influenza or COVID vaccines?
The CDC ACIP indicates that co-administration of the RSV vaccine with other vaccines is acceptable. There are limited data on the immunogenicity and safety of coadministration with other vaccines. The immune response to influenza is similar or only slightly less when given at the same time as the RSV vaccine. It is possible that co-administering RSV vaccine with other vaccines at the same visit might increase local or systemic reactogenicity. When deciding whether to coadminister other vaccines with RSV vaccine, providers should consider whether the patient is up to date with currently recommended vaccines, the feasibility of returning for additional vaccines, and patient preferences. If feasible, spacing out vaccines by at least 2 weeks between visits may be better tolerated by patients.

Is this vaccine covered by insurance? How much will it cost for patients?
The vaccine is covered by Medicare Part D, but not part B. Patients who do not have Part D coverage may have a significant out of pocket cost ($200-$300). At this time, private insurance coverage is variable.

Are the RSV vaccines safe in immunosuppressed patient populations/cancer patients?
Both vaccines are protein based, not live attenuated vaccines. Other protein-based vaccines are considered safe for use in immunosuppressed patients (including post-transplant and cancer patients), for example vaccines such as Hepatitis B and Tdap are safe in these patient populations. Because the RSV vaccines were not tested in immunocompromised patients, specific safety information for this population is not available. We also do not know how effective they are at protecting patients with weakened immune systems.

My patient is requesting this vaccine post-transplant. When can it safely be given?
Hematopoietic stem cell transplant (HCT)/CAR-T cell therapy: Currently, there are no national recommendations for routine RSV vaccination for HCT recipients, as data on efficacy and optimal timing for vaccination are unknown in these patients. We suggest offering to patients who are eligible (>= 60 years of age) and are at least 3 months post-HCT/CAR-T cell therapy using a shared clinical decision-making approach. In patients who are eligible and wish to be vaccinated, fall is the ideal time to vaccinate (before RSV season begins)
Solid organ transplant (SOT): For patients who have received solid organ transplants, they should wait at least one month after transplant or ATG to receive the vaccine. Waiting longer after transplant will likely improve immunogenicity, but early vaccination should be prioritized during respiratory virus season.

What are adjuvanted vaccines and are they safe for my patients?
Adjuvants are combined with the main vaccine agents to improve responses to vaccine. Two other adjuvanted vaccines have been approved by the FDA and are currently in use: the herpes zoster vaccine (Shingrix) and an adjuvanted
influenza vaccine (FluAD). The Arexvy vaccine is adjuvanted, while the Abrysvo vaccine has no adjuvant. The adjuvant used in the Arexvy is also used in the herpes zoster vaccine (Shingrix), although the adjuvant dose in the RSV vaccine is lower, so is felt to be safe. Adjuvanted vaccines may cause minor side effects such as sore arm.

**My patient has received an anti-CD-20 antibody (e.g. rituximab), can they be vaccinated?**

There is no data to support a recommendation at this time. In patients who are eligible and wish to be vaccinated, ideally the vaccine should be given 6 months after the last dose of rituximab. During RSV season, vaccination can be considered, however, response rates are likely to be significantly lower than in immunocompetent hosts.

**My patient is neutropenic, can they get the vaccine?**

In patients who are neutropenic with ANC < 500s, we suggest waiting until count recovery to administer vaccine. It is unknown how effective the vaccine will be in those undergoing therapy for leukemia or other major hematologic malignancies.

**My patient is receiving IVIG, can they get the vaccine?**

Similar to other protein-based vaccines there is no need to delay either RSV vaccine if the patient has received IVIG.

**Can patients younger than 60 receive the vaccine?**

Abrysvo is FDA approved for pregnant individuals between 32 and 36 weeks of gestational age to confer RSV protection to young infants. ACIP recommendations for RSV vaccination in pregnant women are forthcoming. Among other individuals under 60 years of age who are at increased risk of severe RSV due to their immune status, neither Arexvy nor Abrysvo are FDA-approved. Future studies evaluating efficacy in younger patient populations are currently underway, so vaccination recommendations may change in the future.

**Where is the vaccine available?**

This vaccine will be available at some clinics across UW Medicine in October. Contact your clinic manager to determine if your clinic will be providing the vaccine. The vaccine will not be provided during inpatient admissions. The vaccine is also available at many local pharmacies. Please contact your local pharmacy for more information.

**What other RSV prevention options are available?**

It is important to remind patients to avoid sick contacts, particularly children with respiratory symptoms during the fall and winter, when RSV is most commonly transmitted. Washing hands/using hand sanitizer and wearing masks in public places can also help limit RSV exposures. For infants and certain young children, monoclonal antibodies are also available to prevent severe RSV.

**Educational materials:**


**References:**


Arexvy. Package Insert. [https://www.fda.gov/media/167805/download](https://www.fda.gov/media/167805/download). Revised 5/2023

